Biosimilar drugs are developed according to established and specific requirements from the EMA and have proven similar efficacy, quality and safety compared to reference drugs. They have cost-saving potential that can contribute to the sustainability of health care. Concerns raised on the use of a biosimilar drug are the same as those with the corresponding original drug. Head-to-head clinical trials and post-authorisation studies are carried out to clarify any concern.